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Abstract  
Background: Necrotizing enterocolitis (NEC) is a costly gastrointestinal disorder that 
mainly affects preterm and low birth weight infants and can lead to considerable 
morbidity and mortality. Mother’s own milk is protective against NEC but is not always 
available. In such cases, donor human milk has also been shown to be protective (albeit 
to a lesser extent) compared with formula milk, but is more expensive. This systematic 
review aimed to evaluate the cost of donor milk, the cost of treating NEC and the cost-
effectiveness of exclusive donor milk vs formula milk feeding to reduce the short-term 
health and treatment costs of NEC.  
Methods: We systematically searched five relevant databases to find studies with 
verifiable costs or charges of donor milk and/or treatment of NEC and any economic 
evaluations comparing exclusive donor milk with exclusive formula milk feeding. All 
search results were double-screened.   
Results: Six studies with verifiable donor milk costs and 17 with verifiable NEC 
treatment costs were included. The types of cost or charge included varied considerably 
across studies so quantitative synthesis was not attempted.  Estimates of the excess 
length of stay associated with NEC were approximately 18 days for medical NEC and 
50 days for surgical NEC. Two studies claimed to report economic evaluations but did 
not do so in practice.   
Conclusions: It is likely that donor milk provides short-term cost savings by reducing 
the incidence of NEC.  Future studies should provide more details on cost components 
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included and a full economic evaluation including long-term outcomes should be 
undertaken.   
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Introduction  
Globally, approximately 1.1m preterm (<37 weeks gestation) infants die each year, with 
the infant mortality rate for preterm infants at least three times that for term infants1. One 
condition mainly affecting preterm or low birth weight (<2,500g) infants is necrotizing 
enterocolitis (NEC)2. The incidence of NEC in developed countries is up to 13% 
amongst low birth weight infants and/or those born before 33 weeks2.  NEC is usually 
treated medically with bowel rest and systemic antibiotics but more severe cases are 
treated surgically via peritoneal drainage and laparotomy2,3.  A systematic review 
suggested an overall mortality rate of around 20%4, with up to five-fold higher mortality 
amongst those requiring surgery5.  
 
Many agree that breast milk is a natural prophylactic for NEC6-8 and mother’s own 
breast milk is clearly the optimal choice for all infants for this, plus many other reasons9.  
However, mothers with preterm babies may not be able to produce enough milk, may 
be too ill to breastfeed or may die in childbirth10. In this situation, the World Health 
Organization and others recommend using donor human breast milk (donor milk) which 
confers a number of advantages over the alternative of formula milk9,11-13.  A recent 
systematic review7 reports that donor milk reduces the risk of NEC by almost two-thirds 
compared with formula.  However, not all preterm babies who do not receive their 
mother’s own milk receive donor milk instead14,15.  Donor milk is more expensive than 
formula and while it confers various health benefits, it is not known whether its use is 
cost-effective16-18. 
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We therefore undertook a systematic review to answer the following questions: 
1. What is the cost of donor milk? 
2. What is the initial cost to the health service of treating medical and surgical NEC? 
3. Is exclusive donor milk feeding cost-saving and/or cost-effective compared to 
exclusive formula milk feeding when considering its impact on the short-term cost and 
health outcomes associated with NEC? 
 
Materials and Methods 
The protocol was registered on PROSPERO (reference number CRD42016042581).   
 
Eligibility criteria 
 Participants: All infants  
 Intervention: Exclusive donor human breast milk  
 Comparison (for economic evaluation studies): Exclusive formula milk  
 Outcomes: Cost of donor milk, short-term health service cost of treating NEC 
(medical and surgical), cost-effectiveness of donor milk in terms of the short-term 
health and health service costs of NEC.  We did not specify a definition of NEC. 
Short-term is defined as the time from birth to initial post-natal discharge.  Costs data 
had to be ‘verifiable’ i.e. specified the data source.  We sought costs data but 
included charges (to the patient or other payer) if costs were not reported. 
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 Study design: Any study reporting costs of donor milk and/or NEC, or any form of 
economic evaluation. Protocols, opinion pieces/editorials and abstracts were 
excluded. 
 Language and date: Due to resource constraints, only English language studies were 
included. We only sought studies published since January 1996 to recognise 
expected changes in cost structures over time.     
 Publication status: Grey literature was sought. 
 
Search methods 
We carried out two search strategies; the first to identify costs of donor milk and the 
second to identify costs of treating NEC. Both search strategies were also used to 
identify studies including any form of economic evaluation. For both searches the 
following databases were used: CINAHL, Cochrane Central Register of Controlled Trials 
(CENTRAL), EMBASE, Medline and Google Scholar. The last searches were 
undertaken on 11/10/16 for donor milk and 25/10/16 for NEC costs.  AB conducted the 
searches. 
Our broad search terms (as title or keyword) were as follows: 
 Donor milk: We used a combination of [Human milk or donor milk or donor human 
milk or donor breast milk or milk bank*] AND [cost or economic* or value or budget or 
fee or saving or income or price or expense]. 
 NEC: We used a combination of [NEC or necrotising enterocolitis or necrotizing 
enterocolitis] AND [cost or economic* or value or budget or fee or saving or income 
or price or expense]. 
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The full search strategy can be found in Supplementary File 1.  For both searches, the 
references of any relevant reviews or studies meeting the eligibility criteria were 
checked to identify any further studies/sources.   
 
Study selection 
The search results were de-duplicated using EndNote v7. Both authors independently 
screened all of the titles and abstracts against the eligibility criteria. All studies that 
either author thought should be included were added to a full text list. These studies 
were then read independently in full and each author made a decision on whether or not 
each study should be included. Discrepancies were discussed until agreement was 
reached.  
 
Data collection process and data items 
Data extraction was initially undertaken by AB and checked by CT.  A data extraction 
template was designed in Excel for each of the donor milk and NEC treatment costs 
research questions including the following details: 
 Donor milk: cost, units, year of costing, country/currency, cost components included 
(e.g. transport, payments to donors) and whether cost or charge.  
 NEC treatment: cost by type (medical/surgical), year of costing, country/currency, 
cost components included (e.g. indirect costs such as “hotel” or overhead costs and 
physician fees), whether data were collected from a primary research study (i.e. with 
individual infants) or from a secondary source (i.e. generalised costings), sample size 
for primary studies, infants included/excluded (e.g. by birth weight, early mortality), 
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definition of NEC, cost sources, whether cost or charge, whether costs/charges were 
adjusted for infant characteristics (in primary studies) and whether total cost of 
treatment or incremental (compared with an infant without NEC). We also extracted 
data on the length of stay associated with NEC. 
 
Costs as opposed to charges, and incremental rather than total values were extracted if 
both were provided; although total (non-incremental) values were also extracted where 
these provided more detailed results (e.g. a breakdown by type of NEC or standard 
deviations).  Values adjusted for infant characteristics were reported where available.  
For NEC treatment costs, the mean and standard deviation costs/charges were 
reported where provided.  Exceptions (e.g. where a study only reported median values) 
were noted.  For the economic evaluation studies, we planned to summarise information 
on sources of costs and effectiveness data and the methods used in calculating cost 
savings or cost-effectiveness, together with study results and details of any sensitivity 
analysis. 
 
Strategy for data synthesis 
All costs were inflated to 2015 local currency units and converted to 2015 US Dollars at 
purchasing power parity (PPP) using the World Bank Consumer Price Index and 
exchange rates1919. For each estimate of the cost of donor milk, we calculated the cost 
per 100ml as well as an indicative cost per infant in two scenarios. The first scenario 
was use with an infant with birth weight 500-1,250g fed only with donor milk for their 
initial hospital stay, based on a total consumption of 11 litres as estimated from the data 
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presented in Cristofalo et al.’s recent randomised controlled trial20. The second scenario 
was use of donor milk for an average infant <33 weeks or <1500g admitted to neonatal 
intensive care, using the mean consumption of 2.1 litres per infant from Carroll and 
Herrman’s study21. The volume of donor milk per infant varied considerably in this study 
(range 3-9,271ml where used; 28% received none) and was dependent on the method 
of feeding at discharge. However, we use the overall mean (including infants who did 
not receive any donor milk) because it is not always possible to know an infant’s method 
of feeding at discharge at the time donor milk would be initiated (and the ethics of 
rationing use to only those mothers definitely intending or able to breastfeed are also 
questionable). We aimed to synthesise data on donor milk and NEC treatment costs by 
calculating mean costs across studies where there were sufficient comparable studies 
available, using appropriate sub-groups (e.g. by country) if necessary. Where 
comparable data were not available, quantitative synthesis did not occur and a 
descriptive analysis was carried out.  The results of the economic evaluation studies 
were summarised individually. 
 
Results 
Study selection  
The numbers of studies screened, assessed for eligibility and included and excluded in 
the review can be seen in Figure 1.    
 
Cost of donor milk 
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Seven estimates of the cost of donor milk were reported across six studies4,21-26.  The 
cost per 100ml donor milk in each study can be seen in Table 1. Only one study 
reported the cost of production4, which at $51/100ml was actually considerably larger 
than any of the studies reporting charges (to the health service).  The authors noted that 
improvements in how the milk banking service was organised could reduce this cost to 
a more comparable $21/100ml4.  As most milk banks are not for profit we would expect 
there to be little practical difference between costs and charges, with the latter ranging 
from $8/100ml26 to $21/100ml25. The lowest two charges were actually those from milk 
banking services that made a monetary payment to donors to compensate them for the 
time and effort required to pump milk26.  Although the small number of studies from any 
one country or region warrants caution, donor milk appears to be particularly expensive 
in the UK compared to in the US and Scandinavia.  We calculated the mean cost for the 
four US studies ($14 per 100ml, with indicative costs of $1,500 per infant fed only on 
donor milk and $286 per infant), but note that the four estimates differed in terms of the 
cost components included. Due to large variation in costs between settings we did not 
attempt any further quantitative synthesis. 
 
NEC Treatment costs and length of stay 
A total of 17 studies reported one or more values for NEC treatment costs3,4,6,23,25,27-38.  
Table 2 details the NEC treatment costs and length of stay in each study separated by 
whether costs/charges were provided and whether these were incremental to those for 
an infant without NEC or total costs for an infant with NEC.  Further characteristics of 
each study, including the definition of NEC employed (if provided), can be found in 
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Supplementary File 2.  Due to the variation between studies in infant birth weight, 
definition of NEC, type of NEC treatment including the specific surgical procedure, 
which cost components were included, and healthcare context, there is a very large 
overall range of results in Table 2 and quantitative synthesis of costs data was not 
thought to be appropriate.  For example, the lowest value of $3,025 was for the 
incremental cost of medical NEC (no definition provided) excluding indirect, “hotel” and 
physician costs32, while the highest value of $604,526 was for the total charge for small 
bowel surgery (using ICD-9 code 777.5)37.  Even between two seemingly comparable 
US studies, reported one year apart, the incremental cost of medical NEC had a five-
fold variation, from $14,51129 to $77,94823.  NEC treatment costs also appear variable 
within studies.  Where means and standard deviations were reported, the coefficient of 
variation ranged from 0.20 (incremental costs for surgical NEC from Ganapathy et al.23) 
to 0.98 (total charges for large bowel surgery from Zhang et al.37) although values of 0.3 
to 0.4 were typical. 
 
Length of stay data are more comparable between studies.  Three studies reported 
estimated median total (non-incremental) length of stay for surgical NEC based on 
primary data collection3,31,36, which ranged from 51 to 104 days. One further study 
reported an estimate of the mean of this parameter of 72 days37.  Based on the results 
of Bisquera et al.38 and Ganapathy et al.23, the incremental length of stay due to surgical 
NEC (compared to that for an infant without NEC) is likely to be around 50 days.  Fewer 
studies reported primary data for medical NEC, with one estimate of total median length 
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of stay of 36 days36, of which around half are likely to be the incremental length of stay 
associated with NEC23,38.   
 
Economic evaluation of donor milk compared with formula milk 
We initially identified three economic evaluations4,32,39.  While none of these met all of 
our inclusion criteria, it is important to consider why and to discuss other limitations of 
the two studies that claimed to provide economic evaluations of the use of donor milk.  
Wight32 presented a return on investment analysis for the use of donor milk for very low 
birth weight infants (<1,500g).  Three outcomes were considered: NEC, sepsis and 
overall length of stay (for any reason related to the use of human milk rather than 
formula).  The analysis was based on local treatment costs of NEC and sepsis and daily 
“hotel” costs, but excluding physician fees.  The unit cost of donor milk was provided by 
the local milk bank.  Effectiveness data were taken from a single, non-randomised study 
comparing the use of fortified mother’s own milk (not donor milk) with formula40, which is 
problematic as donor milk is unlikely to be as effective as mother’s own milk4 (although 
for ethical reasons there are no “head-to-head” trials of donor milk vs. mother’s own 
milk).  In the economic analysis, infants could be fed with donor milk for either one or 
two months, although no rationale for these durations was provided and effectiveness 
was assumed to be equal regardless of duration of use.  The method of calculating total 
milk requirements (2,000ml for one month or 7,100ml for two months) was not 
described.  Formula milk was assumed to be free of charge.  The year of costing was 
not specified and no sensitivity analysis was performed. 
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Arnold39 claimed to present three models of the cost-effectiveness of banked donor milk 
for the prevention of NEC in preterm infants.  The first model repeated Wight’s results.  
The second model multiplied length of stay data from Schlaner et al.’s study40 by 1997 
daily Neonatal intensive care unit charges to give a length of stay-based charges 
saving.  Donor milk unit costs were stated but could not be verified.  Donor milk was 
assumed to be provided for 60 days (a rationale for this duration was not provided), 
although a clear description of how the total volume of donor milk required was 
included.  Formula milk was assumed to be free of charge.  No sensitivity analysis was 
performed. The third model claimed to calculate the preventable costs of NEC to the US 
state of Texas (i.e. comparing the cost of NEC in the scenario where all preterm infants 
were fed human milk (either mother’s own milk or donor milk) to the current scenario 
where some infants were not fed with human milk but with formula instead).  NEC costs 
were taken from Bisquera et al.’s study38, although this study actually provides charges 
and not costs.  No consideration of the cost of donor or formula milk was included, so 
this model cannot be described as an economic evaluation.  The reduction in the 
incidence of NEC from the use of donor milk was calculated by subtracting the 1.2% risk 
of NEC in infants fed donor milk in a small randomised UK study41 from the 10.1% risk 
of NEC for all infants (regardless of type of milk) in the US42. This is problematic 
because differences in study contexts reduce comparability and a failure to consider 
that the 10.1% risk for all infants is a weighted average of the risks for human and non-
human milk and not a sum of the risks in these two feeding conditions.  
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The main intervention being evaluated in Renfrew et al.’s economic evaluation4 was the 
provision of a lactation consultant to help mothers breastfeed their own infants.  The use 
of donor milk was considered in a secondary analysis, as an adjunct to mother’s own 
milk, so the comparison was not between exclusive use of donor milk and exclusive use 
of formula.   
 
Discussion 
We found six studies including verifiable costs or charges of donor milk. Four of these 
were conducted in the US and the mean cost of donor milk across these studies was 
approximately $14 per 100ml.  Based on existing estimates of donor milk use20,21, this 
would equate to costs of just under $300 per very low birth weight infant and of around 
$1,500 for an infant fed entirely on donor milk.  We found 17 studies including initial 
costs to the health service/charges for the treatment of NEC; however there was 
insufficient comparability between the estimates provided to enable quantitative 
synthesis.  Many studies did not even report what cost components were or were not 
included in their estimates. In particular, studies reporting the cost of donor milk did not 
include the fixed costs of setting up a milk bank (meaning the costs reported here are 
underestimates) or which specific tests on donors and their milk were undertaken.  In 
addition, studies only reporting charges are particularly difficult to synthesise as cost to 
charge ratios vary between hospitals.  Even within primary studies evaluating the cost of 
treating NEC, there was considerable variation between costs for individual infants 
suggesting that costs are also affected by a range of other factors/comorbidities. Future 
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costing studies should clearly specify which costs are included, if possible using a 
“bottom-up” approach to costing.  
 
Estimates of (excess) length of stay are easier to compare than NEC treatment costs 
and enable local bed-day costs to be applied by others wanting to estimate the financial 
impact of NEC on their own institution.  The results of primary studies suggested that 
medical NEC would add around 18 days to an infant’s length of stay and surgical NEC 
around 50 days.   
 
It is, however, clear that the incremental costs of treating infants with NEC are large so 
any potential preventative measures are worthy of consideration.  We were unable to 
include any economic evaluations of exclusive donor milk vs. formula milk in our review, 
even if we extended the outcomes included beyond NEC.  Wight32 and Arnold39 both 
suggested that exclusive donor milk could be cost-saving and would therefore dominate 
the use of formula milk for preterm infants.  However neither study is of sufficient 
methodological quality to provide convincing evidence of the cost-effectiveness of donor 
milk. Our protocol did not include the use of the results from our review of costs in a 
“back of the envelope” economic evaluation which could be subject to similar concerns 
regarding methodological quality. Therefore, while we believe it is likely that the use of 
donor milk would be at least cost-effective, and possibly also cost-saving compared with 
formula milk, we agree with others16-18 that a full economic evaluation is warranted.  
Such an evaluation could consider both the use of exclusive donor milk vs. exclusive 
formula milk, different durations of donor milk feeding (with differential effectiveness) 
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and/or the use of donor milk as a complement or ‘top-up’ to mother’s own milk while 
breastfeeding is being established. It should include all the major short and long-term 
health (and associated cost) consequences related to the use of donor rather than 
formula milk (not just NEC) and potentially issues related to the acceptability of donor 
milk to parents18,43,44.  While our results provide a starting point, any economic 
evaluation will need to clearly justify the costs of donor milk and NEC used as 
parameter inputs and, given the wide range of costs in the studies included in this 
review, it should include a range of sensitivity analyses to determine the robustness of 
the results to different costs of donor milk and NEC treatment. It may also be helpful to 
contact milk banks directly for costs data as part of an economic evaluation. 
 
Our review is not without its limitations.  On the cost of donor milk, we did not compare 
donor milk practices and organisation, health systems or breastfeeding cultures in each 
of the countries in which the included studies were undertaken and it may be that the 
large variation in costs is partially explained by such differences, which may even exist 
within countries. In the UK, for example, England tends to be served by local milk banks 
(N=14 nationwide) while one bank covers the whole of Scotland45. On the cost of NEC, 
we did not specifically search for studies assessing length of stay that did not also 
include costs so we may have missed some primary studies. On economic evaluations, 
our inclusion criteria meant that only studies comparing the use of exclusive donor vs. 
formula milk were included. The use of exclusive donor milk is rare in practice (but may 
occur, for example, where a mother dies in childbirth or is HIV positive and cannot 
safely breastfeed). This restriction was intended to ensure a consistent comparator so 
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that we could synthesis results across studies but may mean we have excluded studies 
that would have provided an insight into the cost-effectiveness of donor milk. We did not 
compare donor milk with mother’s own milk because the latter would clearly dominate in 
an economic evaluation, being both cheaper and at least as effective. Using the idea of 
extended dominance, if exclusive donor milk was found to be cost-effective compared 
with formula, then using donor milk as an adjunct to mother’s own milk would be even 
more so. This is because the cost of donor milk would be reduced by over 70% and 
health outcomes would be at least as good. 
 
We focused on the incidence and short-term costs of NEC as the only outcome 
associated with the use of donor milk.  It may also be the case that donor milk reduces 
the severity of NEC, although to claim this we currently need to generalise from the 
results of a study using mother’s own milk46.  There are many other potential benefits of 
human milk such as reduced neurodevelopmental complications, neonatal infections 
and improved cardiovascular health47-50, as well as potential risks if safety standards are 
not maintained17 and a possible link with slower weight gain7.  These additional 
outcomes would have implications for both the costs and health outcomes associated 
with the use of donor milk. Spill-over effects should also be considered. One concern is 
that the provision of donor milk ‘crowds out’ mother’s own milk and this reduces 
breastfeeding rates. However a recent systematic review suggests that this is not the 
case in practice51. The studies identified were all carried out in developed countries, 
which may limit the international generalisability of the findings and publication bias may 
also be a problem, particularly for any economic evaluations that did not find positive 
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evidence of the use of donor milk.  While we used Google Scholar in an attempt to find 
grey literature we were unable to evaluate the extent of publication bias.  We may also 
have missed studies published in languages other than English.  In an attempt to 
maximise the credibility of our findings, we excluded studies where costs could not be 
‘verified’ i.e. traced back to their original source.  However no other quality appraisal of 
costing studies was undertaken.  We also excluded a study where donor milk was 
purchased on the open market rather than from an official milk bank52.  
 
Conclusion 
It is likely that the use of donor milk is cost-effective. To strengthen the evidence base 
there is a need for a comprehensive economic evaluation of the use of donor milk, 
focusing on providing evidence in contexts where the use of donor milk is not currently 
standard practice. Such work should carefully describe how the costs of donor milk and 
of its implications for healthcare have been generated, given the variability in the 
estimates we have identified between contexts, and, for some outcomes, also within 
contexts. 
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Table 1. Cost/charge of donor milk per 100ml and indicative cost per infant (for exclusive use of donor milk and use as an adjunct 
to mother’s own milk) and inclusions in cost/charge. All values are reported as 2015 USD at PPP. Cost/charge components marked 
as Y for included (value where provided), N for not included, and blank if not reported. 
 
Author Country Cost/ 100ml Cost per 
infant, 
exclusive 
donor milk 
(11l) 
Cost per 
infant, 
donor milk 
as adjunct 
(2.1l) 
Payment to 
donor? 
Processing Transport 
to User 
 
Handling Cost/Charge (to user) 
Jegier et al.22  USA 14.41 1,585 303 N    Charge 
Ganapathy et al.23 USA 10.68 1,175 224 N Y Y Y Charge  
Carroll et al.21 USA 14.24 1,566 299 N  N  Charge 
Huertas24 USA 15.21 1,673 319 N Y   Charge 
USA Mean USA 13.64 1,500 286      
Renfrew et al.4 UK 51.05 5,612 1,072 N    Cost 
Pokhrel et al.25 UK 21.30 2,343 447 N  4.81  Charge 
Arnold26 Denmark 9.87 1,086 207 2.68    Charge 
Arnold 26 Sweden 8.04 884 169 1.67    Charge (out of county hospitals) 
Note: Studies are ordered by country and then by date. 
 
Table 2. Initial hospitalization costs/charges of NEC and inclusions in cost/charge (in addition to direct treatment costs). All costs/charges are 
reported as 2015 USD at purchasing power parity (PPP) and means are reported unless specified. Cost/charge components marked as Y for 
included, N for not included, and blank if not reported. Costs/charges are reported as means (±standard deviation)/reference values from 
secondary sources unless stated. 
 
Author Country Birthweight Total 
cost/ 
charge 
Medical 
cost/charge 
Surgical 
cost/charge 
Indirect costs 
(“hotel”/overheads) 
included? 
LOS  Physician 
fees 
included? 
Primary (P) 
/Secondary 
(S) data 
Total (non-incremental) costs/LOS 
Weimer27 USA All   178,758 Y 39 days N S 
Bartick et al.28 USA 1500-2499g  92,834  Y   S 
Johnson et al.29 USA <1500g 111,298 ± 
46,217 
  Excl overheads Mean 87 days N P 
Johnson et al.6  USA <1500g,  
<35 weeks 
gestation 
185,980 ± 
104,079 
157,252 ± 
64,614 
323,875 ± 
151,991 
Y Mean 85 days  P 
Stey et al.3 
Peritoneal drainage  
USA All   280,987 ± 
97,787 
Y Median 51 days  P 
Stey et al.3 
Peritoneal drainage 
and laparotomy 
USA All   405,257 ± 
133,903 
Y Median 104 days  P 
Stey et al.3 
Laparotomy 
USA All   347,994 ± 
108,844 
Y Median 91 days  P 
Smith et al.30 Australia 1500-1999g 30,733   Y   S 
Struijs et al. 31 
Early closure 
Netherlands All   134,980 
(Median) 
Y Median 100 days Y P 
Struijs et al. 31 
Late closure 
Netherlands All   140,209 
(Median) 
Y Median 96 days Y P 
Incremental costs/LOS 
Wight32 USA All  3,025  N  N S 
Ganapathy et al.23 USA ≤ 28 weeks  77,948 ± 
28,389 
208,594 ± 
40,846 
 Medical mean 12 days; 
Surgical mean 43 days 
N P 
Johnson et al. 29  USA <1500g 17,056 14,511 24,665 Excl overheads Difference in means 16 
days 
N P 
Johnson et al. 29  USA <750g 20,942   Y excluding 
overheads 
 N P 
Johnson et al. 29 USA 750-999g 16,707   Y excluding 
overheads 
 N P 
Johnson et al.29 USA 1000-1249g 11,890   Y excluding 
overheads 
 N P 
Johnson et al. 29 USA 1250-1499g 9,627   Y excluding 
overheads 
 N P 
Johnson et al.6 USA <1500g,  
<35 weeks 
gestation 
47,144   Y Difference in means 15 
days 
 P 
Colaizy et al. 33 USA <1,500g  24,023 35,699 Y 17 days Y S 
Renfrew et al.4  UK 500-999g  49,518 96,877 Y Medical 32 days; 
Surgical 66 days 
Y S 
Renfrew et al.4  UK 1000-1749g  29,379 57,425 Y Medical 19 days; 
Surgical 39 days 
Y S 
Renfrew et al. 4 UK 1750-2500g  44,579 72,625 Y Medical 35 days; 
Surgical 55 days 
Y S 
Pokhrel et al.25* UK All  26,797 29,151 Y 27 days Y S 
Mahon et al. 34* UK All  25,158 27,711 Y 27 days Y S 
Drane35 Australia 1500-1999g  14,469 19,113 N  Y S 
Drane35 Australia <1500g  25,548 49,904 N  Y S 
Total (non-incremental) charges/LOS 
Abdullah et al. 36 USA All 233,524 193,851 350,519  Medical median 36 days 
Surgical median 62 days 
 P 
Zhang et al. 37 
All surgical 
USA All   507,811 ± 
457,732 
 Mean 72 days  P 
Zhang et al. 37 
Small bowel 
USA All   604,526 ± 
487,942 
 Mean 87 days  P 
Zhang et al. 37 
Large bowel 
USA All   463,267 ± 
453,054 
 Mean 65 days  P 
Zhang et al. 37 
Small and large 
bowel 
USA All   531,170 ± 
423,001 
 Mean 79 days  P 
Incremental charges/LOS 
Bisquera et al. 38 USA <1500g  121,015 305,739  Difference in means 
Medical 22 days 
Surgical 60 days 
N P 
Abbreviation: LOS: Length of stay 
Notes: * Pokhrel et al. and Mahon et al. use the same underlying sources (UK Department of Health Reference Costs and NHS Hospital Episode Statistics) and approach to calculating costs but 
the data are based on different years. Studies are ordered by country and then by date. 
 Abbreviations: DM: Donor milk; NEC: Necrotizing enterocolitis 
Figure 1. Study selection flow diagram 
DM costs search NEC costs search
Studies before de-
duplication
Additional records identified 
through other sources
Studies before de-
duplication
N=2,342 N=8 N=678
Studies after de-duplication Studies after de-duplication
N=1,669 N=256
Records excluded Records screened Records screened Records excluded
N=1,637 N=1,669 N=256 N=233
Full-text articles excluded Full-text articles assessed for 
eligibility
Full-text articles excluded
N=27 N=63 N=12
Lack of actual costs or costs taken from 
another (included) study (N=22)
Lack of actual costs or costs taken from 
another (included) study (N=9)
No verifiable costs (N=1)
Not an official milk bank supply (N=1)
Studies selected for DM 
costs
Studies identified as economic 
evaluations
Studies selected for NEC 
costs
No verifiable costs (N=1)
Unable to calculate cost per unit (N=1)
Unable to calculate cost per unit (N=2)
Unable to separate costs of DM (N=1)
N=6 N=3 N=17 Unable to separate initial and long-
term NEC costs (N=1)
(N=2 also selected for DM costs; 
N=1 also selected for NEC and DM 
costs)
Studies included as economic 
evaluations
N=0 (see text)
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Supplementary File 1: Full search strategy  
 
Final search criteria 11.10.16 – Donor milk 
 
Medline = 601 hits 
1. Human milk.mp. or Milk, Human/ 
2. donor milk.mp. 
3. donor human milk.mp. 
4. donor breast milk.mp. 
5. Milk Banks/ or milk bank*.mp. 
6. 1 or 2 or 3 or 4 or 5 
7. cost.mp. or “Costs and Cost Analysis”/ 
8. economic*.mp. 
9. Economics/ or economics.mp. 
10. value.mp. 
11. Budget.mp. or Budgets/ 
12. fee.mp. or “Fees and Charges”/ 
13. Saving.mp. or Income/ 
14. 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. 6 and 14  
16. limit 15 to (English language and yr=”1996 –Current”) 
 
EMBASE =  586 
1. human milk.mp. or breast milk/ 
2. donor milk.mp. 
3. donor human milk.mp. 
4. donor breast milk.mp. 
5. milk bank*.mp. 
6. 1 or 2 or 3 or 4 or 5 
7. "health care cost"/ or cost.mp. or "cost"/ or "cost effectiveness analysis"/ or "hospital 
running cost"/ or "hospital cost"/ or "hospitalization cost"/ or "nursing cost"/ 
8. cost analysis.mp. 
9. economic*.mp. 
10. value.mp. 
11. budget/ or budget.mp. 
12. fee/ or fee.mp. 
13. 7 or 8 or 9 or 10 or 11 or 12 
14. 6 and 13 
15. limit 14 to (english language and yr="1996 -Current") 
 
CINAHL = 1155 
1. human milk 
2. donor milk 
3. donor human milk 
4. donor breast milk 
5. milk bank* 
6. 1 or 2 or 3 or 4 or 5 
7. cost OR price OR expense OR value 
8. cost AND analysis 
9. economic* 
10. budget 
11. fee 
 2 
12. saving 
13. 7 or 8 or 9 or 10 or 11 or 12 
14. 6 and 13 
15. Limit 14 to (english language and yr="1996 -Current") 
 
Final search criteria 25.10.16 – NEC 
 
Medline = 256 hits 
1. cost.mp. or “Costs and Cost Analysis”/ 
2. economic*.mp. 
3. Economics/ or economics.mp. 
4. value.mp. 
5. Budget.mp. or Budgets/ 
6. fee.mp. or “Fees and Charges”/ 
7. Saving.mp. or Income/ 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. Necrotising enterocolitis.mp. or Enterocolitis, Necrotizing/ 
10. NEC 
11. 9 or 10 
12. 8 and 11 
13. limit 12 to (English language and yr=”1996 –Current”) 
 
EMBASE =  250 
1. "health care cost"/ or cost.mp. or "cost"/ or "cost effectiveness analysis"/ or "hospital 
running cost"/ or "hospital cost"/ or "hospitalization cost"/ or "nursing cost"/ 
2. cost analysis.mp. 
3. economic*.mp. 
4. value.mp. 
5. budget/ or budget.mp. 
6. fee/ or fee.mp. 
7. 1 or 2 or 3 or 4 or 5 or 6 
8. Necrotising enterocolitis.mp. or Enterocolitis, Necrotizing/ 
9. NEC 
10. 8 or 9 
11. 7 and 10 
12. limit 11 to (english language and yr="1996 -Current") 
 
CINAHL = 172 
1. cost OR price OR expense OR value 
2. cost AND analysis 
3. economic* 
4. budget 
5. fee 
6. saving 
7. 1 OR 2 OR 3 OR 4 OR 5 OR 6 
8. NEC 
9. necrotising enterocolitis 
10. necrotizing enterocolitis 
11. 8 OR 9 OR 10 
12. 7 AND 11 
13. Limit 12 to (english language and yr="1996 -Current") 
 
Supplementary File 2: NEC treatment costs/charges additional study characteristics (cells left blank if data not reported) 
 
Author Primary (P) 
/Secondary 
(S) data 
Definition of NEC Infants included/ 
excluded 
Sample size if 
primary data 
Adjustments for 
infant 
characteristics? 
Data source(s) 
Abdullah et al. 
(2010) 
P ICD-9: 777.5 plus 
surgical codes 
All infants (results 
also presented by 
dead/alive) 
<60 days old at 
admission 
20,822 NEC cases 
5,403 surgical 
Y National Inpatient Sample 
Kids’ Inpatient Database (both Agency for 
Healthcare Research and Quality), USA 
Bartick et al. 
(2010) 
S   N/A N/A Extrapolated from Weimer (2001) and 
Bisquera et al. (2002) 
Bisquera et al. 
(2002) 
P Bells criteria  ≥ 2 Alive infants 49 medical NEC + 
98 controls; 37 
surgical NEC + 74 
controls 
N Hospital case notes and charges (2 hospitals 
in the USA) 
Colaizy et al. 
(2016) 
S Bells criteria  ≥ 2 Excluded if died in 
first 3 days 
N/A Y Johnson 2013 results, plus 15% overheads + 
physician fees based on estimated 
incremental LOS 
Drane (1997) S Major episode of illness 
with or without 
significant operation 
 N/A N/A Australian Department of Health, Housing, 
Local Government and Community Services 
1993 
Ganapathy et al. 
(2012) 
P ICD-9: 777.50–777.53 
plus surgical codes 
Excluded if died in 
first 3 days or if daily 
cost<US$100 
259 NEC 
cases/2,560 
82 surgical 
Y California Office of Statewide Health 
Planning and Development Hospital 
Discharge data, USA 
Johnson et al. 
(2013) 
P ICD-9: 777.5, 777.52, 
777.5, 765.01–765.05, 
765.11–765.15 
Excluded if died 
during stay 
29 NEC cases/425 Y Rush University Medical Centre cost 
database, USA 
Costs deflated to be national averages 
Johnson et al. 
(2015) 
P Modified Bell’s criteria ≥ 
2. Surgically: peritoneal 
drain or exploratory 
laparotomy 
Excluded if died 
during stay 
29 NEC cases/291 
5 surgical 
Y (incremental 
only) 
Rush University Medical Centre cost 
database, USA 
Mahon et al. 
(2016) 
S   N/A N/A Costs: UK Department of Health Reference 
Costs 2011/12 
LOS: England Hospital Episode Statistics 
2011/12 
Pokhrel et al. 
(2015) 
S   N/A N/A Costs: UK Department of Health Reference 
Costs 2009/10 
LOS: England Hospital Episode Statistics 
2009/10 
Renfrew et al. 
(2009)  
S Bells criteria  ≥ 2  N/A N/A Costs: UK Department of Health Reference 
Costs 2007/08 
LOS: Bisquera et al. (2002), Stoll et al. 
(2002), Fanaraff et al. (1998) 
Smith et al. 
(2002) 
S ICD-9: 777.5, 777.8  N/A N/A Costs: Australian National Hospital Cost Data 
Collection 1997/98 
Stey et al. (2015) P ICD-9: 777.5, 777.51, 
777.52, 777.53 
 101 Peritoneal 
drainage (PD); 172 
PD+Laparotomy; 
426 Laparotomy  
Y (costs, not 
LOS) 
California Office of Statewide Health 
Planning and Development Linked Birth File 
Dataset, USA 
Struijs et al. 
(2012) 
P   13 Early closure; 62 
Late closure 
N Hospital case notes; Dutch guideline prices 
for economic evaluations 2004 edition 
Weimer (2001) S   N/A N/A Costs/LOS: US Health Care Policy and 
Research National Inpatient Sample 1996 
Wight (2001) S   N/A N Sharp Mary Birch Hospital for Women cost 
database, USA 
Zhang et al. 
(2011) 
P ICD-9: 777.5 plus 
surgical codes 
<60 days old at 
admission 
5,374 surgical NEC 
cases; 2,126 short 
bowel (SB); 963 
long bowel (LB); 
1,282 SB+LB 
N National Inpatient Sample 
Kids’ Inpatient Database (both Agency for 
Healthcare Research and Quality), USA 
Abbreviations: NEC: necrotizing enterocolitis; lOS: Length of stay. 
Please see main text reference list for full references. 
 
 
 
 
